No clear answer
Omega-3 fatty acids: reduce relapses and new lesions in relapsing MS
relapsing MS · Vitamin D and nutritional supplements
Trials have tried this, but none was a controlled phase 2 or 3 trial with a readable result.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 0
- People in controlled trials
- 0
How the verdict was reached
No result yet
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| Omega-3 fatty acids, phase 3 | Phase2|phase3 | 100 | 2004 | Missed its main goal The cumulative number of gadolinium-enhancing MRI lesions during the first 6 months were similar in the ω-3 fatty acids and placebo groups (median difference, 1; 95% CI, 0 to 3; P = .09). Paper abstract | Not counted: not randomised |
Counted: 0. Will count later: 0. Not counted: 1.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026First listed as No clear answer
Related hypotheses
- Vitamin D and nutritional supplements: protect nerve tissue in relapsing MS
- Fish oil: protect nerve tissue in relapsing MS
- Melatonin: protect nerve tissue in relapsing MS
- Fish oil: repair myelin in relapsing MS
- Vitamin D and nutritional supplements: slow disability worsening in relapsing MS
- Cholecalciferol: slow disability worsening in relapsing MS
- Ergocalciferol: slow disability worsening in relapsing MS
- Fish oil: slow disability worsening in relapsing MS
- Melatonin: slow disability worsening in relapsing MS
- Retinol: slow disability worsening in relapsing MS
- Vitamin D and nutritional supplements: reduce relapses and new lesions in relapsing MS
- Cholecalciferol: reduce relapses and new lesions in relapsing MS
- Curcumin: reduce relapses and new lesions in relapsing MS
- Fish oil: reduce relapses and new lesions in relapsing MS
- Melatonin: reduce relapses and new lesions in relapsing MS
- Retinol: reduce relapses and new lesions in relapsing MS
Assembled by software from public sources.